XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Bristol-Myers Squibb generated $11.49B in Q1 2026 revenue, up 2.6% from $11.20B a year ago, while net income came in at $2.68B and GAAP EPS landed at $1.31.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | OPTION_EXERCISE | -1,373 | — | — |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | TAX_WITHHOLD | -599 | $58 | $34,874 |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | OTHER | -203 | — | — |
| 5/1/2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | OPTION_EXERCISE | 1,373 | — | — |
| 4/1/2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | OPTION_EXERCISE | 3,307 | — | — |
| 4/1/2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | TAX_WITHHOLD | -1,692 | $62 | $104,447 |
| 4/1/2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | OPTION_EXERCISE | -3,307 | — | — |
| 4/1/2026 | Elkins David V | EVP, Chief Financial Officer | SELL | -25,519 | $62 | $1,571,970 |
| 4/1/2026 | Elkins David V | EVP, Chief Financial Officer | SELL | -4,481 | $62 | $278,046 |
| 3/31/2026 | YALE PHYLLIS R | — | GRANT | 577.08 | $61 | $35,000 |
| 3/31/2026 | Samuels Theodore R. II | — | GRANT | 845.01 | $61 | $51,250 |
| 3/31/2026 | Rice Derica W | — | GRANT | 638.91 | $61 | $38,750 |
| 3/31/2026 | McMullen Michael R. | — | GRANT | 577.08 | $61 | $35,000 |
| 3/31/2026 | Arduini Peter J | — | GRANT | 577.08 | $61 | $35,000 |
| 3/10/2026 | Hickey Benjamin | President, RayzeBio Org. | GRANT | 11,429 | — | — |
| 3/10/2026 | Hickey Benjamin | President, RayzeBio Org. | GRANT | 17,143 | — | — |
| 3/10/2026 | Shibutani Hiroshi Chris | EVP, Chief Strategy Officer | GRANT | 7,837 | — | — |
| 3/10/2026 | Shibutani Hiroshi Chris | EVP, Chief Strategy Officer | GRANT | 11,755 | — | — |
| 3/10/2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | GRANT | 26,122 | — | — |
| 3/10/2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | GRANT | 39,184 | — | — |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 198,727,768 | $10,719,375,805 | — | 1/29/2026 |
| BlackRock | 158,658,853 | $6,589,102,184 | — | 8/13/2024 |
| State Street | 97,980,438 | $5,285,064,826 | — | 2/13/2026 |
| JP Morgan Chase | 80,716,176 | $4,353,829,442 | — | 2/11/2026 |
| AQR Capital | 25,796,905 | $1,391,485,051 | — | 2/17/2026 |
| Fidelity (FMR) | 10,250,306 | $552,901,570 | — | 2/17/2026 |
| Citadel Advisors | 8,996,231 | $483,750,009 | — | 2/17/2026 |
| Two Sigma | 4,662,042 | $251,470,545 | — | 2/17/2026 |
| Point72 | 3,569,911 | $192,560,999 | — | 2/17/2026 |
| Millennium Management | 2,238,859 | $120,764,054 | — | 2/17/2026 |
| DE Shaw | 1,637,963 | $88,351,724 | — | 2/17/2026 |
| Bridgewater Associates | 408,892 | $22,055,634 | — | 2/13/2026 |